A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

CT.gov Identifier
NCT06295770
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
Mayo Clinic
Collaborator
N/A
Study Contact Information
N/A
Recruiting
Contact Us

Study Details

Diseases
Glomerulonephritis and atypical hemolytic uremic syndrome (aHUS)
Study Drug
Obinutuzumab
See More
Gazyva
Genes
CFI
Study Dates
Jun 2024 - Dec 2026
Sex
Ignored
Age
18+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • * ≥18 years of age
  • * Biopsy proven fibrillary glomerulonephritis
  • * Proteinuria > 1.0 g/24hrs prior to initiation of immunosuppressive therapy
  • * eGFR ≥ 20 ml/min/BSA
Exclusion Criteria:
  • Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy)
  • * Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy)
  • * Hepatitis B, C or HIV positive
  • * Pregnant or breast-feeding
  • * Active infection
  • * Kidney transplant
  • * Anemia with Hgb < 8.0 g/dL
  • * Thrombocytopenia with platelet count < 100'000
  • * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication
  • * Patients who have received cyclophosphamide in the last 6 months
  • * Patients who have received ACTH and/or mycophenolate mofetil in the last 30 days
  • * Patient who are on prednisone therapy at a dose > 10 mg/day in the last 15 days
  • * Patients who received rituximab previously with CD20 count of < 5 cells/microliter at the time of enrollment
  • * For women who are not postmenopausal (greater than or equal to [>/=] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug
  • * For men: agreement to remain abstinent or use two adequate methods for contraception, including at least one method with failure rate of less than 1% per year during the treatment period and for at least 6 months (180 days) after the last dose of drug

Protocol Summary

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.